Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.50 |
| ▸ | OGFRL1 | Q5TC84 | 7/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094992 | 1.00 | OPRM1 (0.50) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7093758 | 0.93 | OPRM1 (0.52) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7096860 | 0.93 | OPRM1 (0.52) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7095474 | 0.92 | OPRM1 (0.47) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7091932 | 0.90 | OPRM1 (0.46) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7092529 | 0.86 | OPRM1 (0.49) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7093844 | 0.86 | OPRM1 (0.53) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7095220 | 0.86 | OPRM1 (0.47) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7093859 | 0.85 | OPRM1 (0.46) | OPRM1OPRK1OPRD1OPRL1OGFRL1 | |
| SCHEMBL7966918 | 0.85 | OPRM1 (0.46) | OPRM1OPRK1OPRD1OPRL1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109549-A1 | 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists | ITO FUMITAKA (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1102762-B1 | 2-SUBSTITUTED-1-PIPERIDYL BENZIMIDAZOLE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6172067-B1 | ANALGESICS, ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109549-A1 | 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists | OPRL1, ORMDL3, OPRM1 | OPRM1 3/4885OPRK1 6/4885OPRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.